Thomas Benfield1, Peter Lange, Jørgen Vestbo. 1. Department of Infectious Diseases 144, Hvidovre University Hospital, DK-2650 Hvidovre, Denmark. tlb@dadlnet.dk
Abstract
BACKGROUND: Respiratory tract infections are a frequent complication of COPD, but little is known about the incidence, association, and risk of infectious diseases related to impaired lung function. METHODS: Participants in the Copenhagen City Heart Study had lung function measured at baseline, and were followed for up to 25 years. All hospitalizations due to any infection were identified through registry linkage. Impaired lung function was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system. MAIN RESULTS: A total of 3,333 infectious disease hospitalizations (IDHs) occurred during 230,653 person-years of follow-up (PY), corresponding to an overall incidence of 145 IDHs (95% confidence interval [CI], 139 to 149) per 10,000 PY. The incidence increased with GOLD stage, from 131 (95% CI, 126 to 136) for normal COPD, to 170 (95% CI, 146 to 193) for mild COPD, to 230 (95% CI, 207 to 253) for moderate COPD, and 394 (95% CI, 330 to 459) for severe/very severe COPD. The trend in risk persisted after the control of background characteristics using Cox proportional hazards analysis (adjusted relative risks: 1.06 [95% CI, 0.92 to 1.23], 1.39 [95% CI, 1.24 to 1.56], and 2.21 [95% CI, 1.84 to 2.64], respectively; p=0.001). In subgroup analysis, the increased risk was associated with lower and upper respiratory tract infections, pyothorax, and tuberculosis, but not with influenza, sepsis, skin infections, urinary tract infections, diarrheal disease, or other infectious diseases. CONCLUSIONS: The presence of obstructive lung disease is a significant predictor of IDH caused by respiratory tract infections, but not of hospitalizations due to infections outside the respiratory system.
BACKGROUND:Respiratory tract infections are a frequent complication of COPD, but little is known about the incidence, association, and risk of infectious diseases related to impaired lung function. METHODS:Participants in the Copenhagen City Heart Study had lung function measured at baseline, and were followed for up to 25 years. All hospitalizations due to any infection were identified through registry linkage. Impaired lung function was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system. MAIN RESULTS: A total of 3,333 infectious disease hospitalizations (IDHs) occurred during 230,653 person-years of follow-up (PY), corresponding to an overall incidence of 145 IDHs (95% confidence interval [CI], 139 to 149) per 10,000 PY. The incidence increased with GOLD stage, from 131 (95% CI, 126 to 136) for normal COPD, to 170 (95% CI, 146 to 193) for mild COPD, to 230 (95% CI, 207 to 253) for moderate COPD, and 394 (95% CI, 330 to 459) for severe/very severe COPD. The trend in risk persisted after the control of background characteristics using Cox proportional hazards analysis (adjusted relative risks: 1.06 [95% CI, 0.92 to 1.23], 1.39 [95% CI, 1.24 to 1.56], and 2.21 [95% CI, 1.84 to 2.64], respectively; p=0.001). In subgroup analysis, the increased risk was associated with lower and upper respiratory tract infections, pyothorax, and tuberculosis, but not with influenza, sepsis, skin infections, urinary tract infections, diarrheal disease, or other infectious diseases. CONCLUSIONS: The presence of obstructive lung disease is a significant predictor of IDH caused by respiratory tract infections, but not of hospitalizations due to infections outside the respiratory system.
Authors: Leonardo M Fabbri; Cynthia Boyd; Piera Boschetto; Klaus F Rabe; A Sonia Buist; Barbara Yawn; Bruce Leff; David M Kent; Holger J Schünemann Journal: Proc Am Thorac Soc Date: 2012-12
Authors: Richard T McKendry; C Mirella Spalluto; Hannah Burke; Ben Nicholas; Doriana Cellura; Aymen Al-Shamkhani; Karl J Staples; Tom M A Wilkinson Journal: Am J Respir Crit Care Med Date: 2016-03-15 Impact factor: 21.405
Authors: A C Pettit; L A Kaltenbach; F Maruri; J Cummins; T R Smith; J V Warkentin; M R Griffin; T R Sterling Journal: Int J Tuberc Lung Dis Date: 2011-07 Impact factor: 2.373
Authors: Malin Inghammar; Anders Ekbom; Gunnar Engström; Bengt Ljungberg; Victoria Romanus; Claes-Göran Löfdahl; Arne Egesten Journal: PLoS One Date: 2010-04-13 Impact factor: 3.240
Authors: Marian Ryan; Jose A Suaya; John D Chapman; William B Stason; Donald S Shepard; Cindy Parks Thomas Journal: PLoS One Date: 2013-10-09 Impact factor: 3.240